New England Journal of Medicine November 18, 2021

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab (COMET-ICE)

Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, et al. (COMET-ICE Investigators)

Bottom Line

In the Phase 3 COMET-ICE trial, early administration of the neutralizing monoclonal antibody sotrovimab profoundly reduced the risk of hospitalization or death among high-risk outpatients with mild-to-moderate COVID-19.

Key Findings

1. Among the 583 patients included in the primary interim analysis, disease progression leading to hospitalization (>24 hours) or death occurred in 3 of 291 patients (1%) in the sotrovimab group compared to 21 of 292 patients (7%) in the placebo group.
2. Sotrovimab treatment resulted in an 85% relative risk reduction for hospitalization or death (97.24% CI, 44 to 96; P=0.002).
3. No deaths occurred in the sotrovimab group prior to day 29, whereas 1 death was reported in the placebo group.
4. The incidence of adverse events was comparable between the two arms, with serious adverse events occurring less frequently in the sotrovimab group than in the placebo group, largely driven by reduced COVID-19 progression.

Study Design

Design
RCT
Double-Blind
Sample
583
Patients
Duration
29 days
Median
Setting
Multicenter, multinational
Population Nonhospitalized adult patients with mild-to-moderate COVID-19, symptom onset within 5 days, and at least one risk factor for severe disease progression (e.g., age >55, diabetes, obesity, chronic kidney disease).
Intervention Sotrovimab 500 mg administered as a single intravenous infusion.
Comparator Matching placebo administered as a single intravenous infusion.
Outcome Composite of all-cause hospitalization (for >24 hours) or death from any cause within 29 days after randomization.

Study Limitations

The trial was conducted before the emergence of the heavily mutated Omicron variant and its sublineages (e.g., BA.2, BA.4, BA.5), which subsequently demonstrated significant in vitro resistance to sotrovimab and negated its clinical utility.
The primary NEJM publication was based on an interim analysis of 583 patients (out of a final 1,057), which inherently limits statistical power for evaluating rare secondary safety endpoints or mortality alone.
The study primarily enrolled unvaccinated individuals, limiting the generalizability of the absolute risk reduction to highly vaccinated or seropositive populations with hybrid immunity.
Intravenous infusion presents logistical challenges for outpatient administration compared to oral antivirals or intramuscular injections (the latter of which was subsequently evaluated in the COMET-TAIL trial).

Clinical Significance

Note on Trial Disambiguation: While the prompt references 'ACTIV-2 sotrovimab outpatient', the ACTIV-2 platform evaluated other monoclonal antibodies (like bamlanivimab and amubarvimab/romlusevimab), whereas sotrovimab was evaluated for inpatients in ACTIV-3 and for outpatients in the landmark COMET-ICE trial. The COMET-ICE trial established sotrovimab as a highly effective early intervention for high-risk outpatients with COVID-19, demonstrating an 85% reduction in hospitalization or death. Because sotrovimab was engineered to target a highly conserved pan-sarbecovirus epitope, it successfully retained neutralizing activity against the Alpha, Beta, Gamma, and Delta variants, filling a critical therapeutic void when first-generation mAbs lost efficacy. These data formed the basis for its FDA Emergency Use Authorization (EUA) in May 2021. Ultimately, the relentless antigenic drift of the Omicron subvariants evaded even this conserved epitope, leading to the revocation of its EUA in early 2022, but the trial remains a premier proof-of-concept for targeting conserved viral motifs.

Historical Context

During the first year of the COVID-19 pandemic, first-generation monoclonal antibodies targeting the receptor-binding motif of the SARS-CoV-2 spike protein (such as bamlanivimab) were developed and authorized. However, as the virus mutated, variants of concern rapidly developed mutational escape, rendering many of these agents obsolete. Sotrovimab (VIR-7831) was uniquely derived from a survivor of the 2003 SARS-CoV-1 outbreak; it targeted an epitope conserved across both SARS-CoV-1 and SARS-CoV-2 that does not directly compete for ACE2 binding. COMET-ICE was launched to test the hypothesis that targeting this conserved region would provide a high barrier to viral resistance while maintaining robust clinical efficacy in outpatients.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

How does the mechanism of action of sotrovimab explain why it must be administered early in the course of COVID-19 rather than during the severe, late-stage inflammatory phase?

Key Response

Sotrovimab is a neutralizing monoclonal antibody that binds to the SARS-CoV-2 spike protein, preventing viral entry into host cells. It is most effective during the early viral replication phase of the disease; once the disease progresses to the severe pulmonary or inflammatory phase (driven by the host's hyperactive immune response rather than peak viral load), blocking viral entry provides little clinical benefit, highlighting the biphasic pathophysiology of COVID-19.

Resident
Resident

Based on the COMET-ICE trial criteria, which specific patient populations benefit most from sotrovimab, and how do you clinical decision-make between using a monoclonal antibody versus oral antivirals like nirmatrelvir/ritonavir in the outpatient setting?

Key Response

High-risk outpatients (e.g., older age, obesity, diabetes, immunosuppression) benefit most. The choice between mAbs and oral antivirals often depends on symptom duration (e.g., within 5 days for oral therapies vs. up to 7 days for mAbs), severe drug-drug interactions (which heavily limit nirmatrelvir/ritonavir use), and current variant susceptibility, making mAbs a vital alternative when oral options are contraindicated or intolerable.

Fellow
Fellow

Sotrovimab targets a highly conserved epitope shared between SARS-CoV-1 and SARS-CoV-2. How does this structural target influence its susceptibility to viral mutations compared to other monoclonal antibodies, and what are the implications for severely immunocompromised patients?

Key Response

Sotrovimab binds to a conserved non-receptor binding motif (RBM) of the spike protein, making it less vulnerable to early spike mutations compared to mAbs targeting the highly mutable RBM. However, in severely immunocompromised patients with prolonged viral shedding, sublethal evolutionary pressure from mAb monotherapy can lead to de novo resistance mutations, necessitating genomic surveillance and potentially combination therapies.

Attending
Attending

Given the rapid evolution of viral variants that eventually rendered sotrovimab less effective in subsequent waves, how should health systems adapt their clinical protocols for deploying highly specific biologic therapies in a dynamically changing pandemic landscape?

Key Response

The transient utility of mAbs like sotrovimab highlights the need for agile healthcare infrastructures that tightly integrate local real-time genomic surveillance with pharmacy supply chains. Attendings must recognize that rigid protocols become obsolete quickly in infectious diseases, requiring constant re-evaluation of therapeutic efficacy based on regional variant prevalence rather than static, historical trial data.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

The COMET-ICE trial demonstrated high efficacy during a specific phase of the pandemic. From a methodological standpoint, how does the emergence of new viral variants post-randomization threaten the external validity of such trials, and what adaptive trial designs could better account for viral evolution?

Key Response

The external validity (generalizability) of therapeutic trials for rapidly mutating viruses is highly time-dependent. Traditional static RCTs may evaluate a drug against a variant that is extinct by the time of publication. Platform trials with adaptive seamless designs, utilizing continuous variant sequencing and surrogate endpoints (like viral clearance time), allow for the dynamic addition or dropping of study arms, providing more robust, real-time clinical evidence.

Journal Editor
Journal Editor

The COMET-ICE trial was stopped early for overwhelming efficacy. As a peer reviewer, what are the inherent statistical and epidemiological risks of early trial termination, and how might it inflate the perceived treatment effect or obscure safety signals?

Key Response

Trials stopped early for benefit (truncated RCTs) often overestimate the treatment effect size due to random high fluctuations at the interim analysis boundary (the 'winner's curse'). Furthermore, truncating follow-up limits the accumulation of safety data, potentially obscuring rare but significant adverse events (e.g., late-onset immune reactions), which a rigorous reviewer would require the authors to explicitly address as a methodological limitation.

Guideline Committee
Guideline Committee

How does the historical evidence from the COMET-ICE trial integrate into current NIH/IDSA COVID-19 treatment guidelines regarding the hierarchy of outpatient therapies, particularly given the dynamic nature of therapeutic recommendations based on prevailing viral variants?

Key Response

While COMET-ICE provided high-quality (Level 1) evidence for sotrovimab's efficacy, guideline committees must weigh this against real-time variant susceptibility. Consequently, guidelines shifted to a modular approach where the recommendation strength of mAbs is conditional upon regional variant data. Guidelines typically place active mAbs as alternatives to oral antivirals (like Paxlovid) when the latter are contraindicated, specifically because mAb efficacy is highly volatile against new variants compared to conserved-target small-molecule inhibitors.

Clinical Landscape

Noteworthy Related Trials

2021

BLAZE-1 Trial

n = 1,035 · JAMA

Tested

Bamlanivimab and etesevimab

Population

Ambulatory patients with mild-to-moderate COVID-19 at high risk for severe disease

Comparator

Placebo

Endpoint

COVID-19 related hospitalization or death by day 29

Key result: The combination of bamlanivimab and etesevimab significantly reduced the risk of COVID-19-related hospitalization or death by 70% compared to placebo.
2021

REGEN-COV Outpatient Trial

n = 4,567 · NEJM

Tested

Casirivimab and imdevimab

Population

Outpatients with COVID-19 and risk factors for severe disease

Comparator

Placebo

Endpoint

COVID-19-related hospitalization or death from any cause

Key result: Treatment with REGEN-COV reduced the risk of COVID-19-related hospitalization or death by 71.3% compared to placebo.
2022

EPIC-HR Trial

n = 2,246 · NEJM

Tested

Nirmatrelvir plus ritonavir (Paxlovid)

Population

Unvaccinated, nonhospitalized adults with COVID-19 at high risk for progression

Comparator

Placebo

Endpoint

COVID-19-related hospitalization or death from any cause through day 28

Key result: Nirmatrelvir/ritonavir reduced the risk of COVID-19-related hospitalization or death by 89% compared to placebo.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis